Diabetes, Diabetes Mellitus, Type 2
Conditions
Brief summary
This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
Interventions
DRUGliraglutide
Sponsors
Novo Nordisk A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy * 7.0 % =\< HbA1c \< 10.0 % * Body Mass Index (BMI) \< 30.0 kg/m\^2
Exclusion criteria
* Subjects treated with thiazolidinediones or insulin * Subjects with any serious medical conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c | after 14 weeks treatment |
Secondary
| Measure | Time frame |
|---|---|
| Glycaemic control parameters (fasting plasma glucose, post prandial plasma glucose) after 14-week treatment | — |
| Body weight after 14 weeks. | — |
| Safety and tolerability | — |
Countries
Japan
Outcome results
None listed